Remove Myocardial Infarction Remove Stent Remove Thrombosis
article thumbnail

Abstract 4132742: Fractional flow reserve guided complete revascularization versus Culprit-only percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease. A meta-analysis of randomized controlled trials

Circulation

vs 13.6%), any stent thrombosis (RR=1.42; 95% CI [0.35, 5.72]; p=0.62; 2.2% vs 13.6%), any stent thrombosis (RR=1.42; 95% CI [0.35, 5.72]; p=0.62; 2.2% However, FFR-guided CR showed no beneficial effect on all-cause mortality, stroke, major bleeding and myocardial infarction.

article thumbnail

Stress hyperglycemia and poor outcomes in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis

Frontiers in Cardiovascular Medicine

Background Hyperglycemia, characterized by elevated blood glucose levels, is frequently observed in patients with acute coronary syndrome, including ST-elevation myocardial infarction (STEMI). 5.11), repeat PCI or stent thrombosis (pooled RR 1.99, 95% CI 1.21–3.28), 2.17), heart failure (pooled RR 1.56, 95% CI: 1.37–1.77),

article thumbnail

Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial

Circulation

Patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention were randomly assigned by center to receive low-dose PPA or matching placebo for at least 48 hours. Circulation, Ahead of Print. mg·kg·h of bivalirudin intravenously). mg·kg·h of bivalirudin intravenously).

article thumbnail

Percutaneous Coronary Interventions Using a Ridaforolimus?Eluting Stent in Patients at High Bleeding Risk

Journal of the American Heart Association

Drug‐eluting stents have been shown to be superior to bare‐metal stents in patients with HBR, even when patients were given abbreviated periods of dual antiplatelet therapy (DAPT). Short DAPT has not been evaluated with the EluNIR ridaforolimus‐eluting stent. presented with acute coronary syndrome; 33.7%

Stent 40
article thumbnail

Clinical outcomes with thin versus thick strut polymer-free biolimus-coated stents at 3 years

Open Heart

Background For high bleeding-risk patients (HBR) undergoing percutaneous coronary intervention (PCI), the LEADERS FREE (LF) and LEADERS FREE II (LF II) trials established the safety and efficacy of a stainless steel polymer-free biolimus-coated stent (SS-BCS) with 30 days of dual antiplatelet treatment (DAPT).

Stent 40
article thumbnail

Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography in the Guidance of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis.

Circulation

The 2 coprimary outcomes were target lesion revascularization and myocardial infarction. The secondary outcomes included ischemia-driven target lesion revascularization, target vessel myocardial infarction, death, cardiac death, target vessel revascularization, stent thrombosis, and major adverse cardiac events.

article thumbnail

Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial

Circulation

Background:Stopping aspirin within 1 month after implantation of a drug-eluting stent (DES) for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome (ACS). Circulation, Ahead of Print. 0.80];P<0.001 for noninferiority;P=0.002 for superiority). versus 3.4%; HR, 0.35 [95% CI, 0.20–0.61];P<0.001).Conclusions:This

Stent 40